Morag Park, Ph.D.

Academic title(s): 

Professor, Diane and Sal Guerrera Chair in Cancer Genetics
Rosalind and Morris Goodman Cancer Institute
Departments of Biochemistry, Medicine and Oncology
McGill University

Morag Park, Ph.D.
Contact Information
Address: 

1160 Pine Avenue West
Montreal, Quebec H3G 0B1
Office: 602B
Lab: 514

Phone: 
514-398-1836 (Office)
514-398-5074 (Lab)
Fax number: 
514-398-6769
Email address: 
morag.park [at] mcgill.ca
Awards, honours, and fellowships: 

1. Chevalière de l'Ordre nationale du Québec

2. Chair of the AACR Tumor Microenvironment Network Elect, The American Association for Cancer Research (AACR),  2014.
3. Fellow of The Royal Society of Canada, 2007


 

Selected publications: 
Current research: 

Dr. Park’s research interests focus on the molecular mechanisms of oncogenic activation of receptor tyrosine kinases and mechanisms for cell transformation using the Met, hepatocyte growth factor (HGF) and oncoprotein as a model. Her group and others have shown that the activity of the HGF receptor is frequently altered in human cancer and they have proposed new models for its mechanism of oncogenic activation. Their current work is aimed at identifying the critical molecular signals regulated by the HGF/SF receptor and receptor tyrosine kinases, in general, that contributes to tumor progression, and are suitable targets for therapeutic intervention.

Dr. Park’s research goals have now developed into a broader interest in understanding how multiple genetic alterations and epigenetic events synergize to promote tumorigenesis and progression in human breast cancer. This research interest will interface with a breast cancer translational research initiative formed through a collaboration with multiple basic researchers at McGill and the MUHC and with surgeons, oncologists and pathologists at the MUHC.

Dr. Park and colleagues are forming a Montreal Breast Cancer Functional Genomics Group that will employ the recent advances in strategies of genomics and proteomics, from the McGill based and worldwide research community, to identify molecular determinants of tumor prognosis, diagnosis and response to therapies.


 

Back to top